Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.55 |
| ▸ | CASP7 | P55210 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 6/20 | 0.53 |
| ▸ | MAOB | P27338 | 6/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PRKCI | P41743 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.46 |
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067461 | 1.00 | CASP1 (0.55) | CASP1CASP7HSD17B10MAOAMAOB | |
| SCHEMBL4878376 | 0.96 | CASP1 (0.55) | CASP1CASP7HSD17B10MAOAMAOB | |
| SCHEMBL30513596 | 0.88 | CASP1 (0.70) | CASP1CASP7HSD17B10MAOBMAPK1 | |
| SCHEMBL460333 | 0.88 | CASP1 (0.70) | CASP1CASP7HSD17B10MAOBMAPK1 | |
| Hydrochloric Acid SCHEMBL3873080 | 0.86 | CASP1 (0.68) | CASP1CASP7HSD17B10MAOBMAPK1 | |
| SCHEMBL929312 | 0.84 | CASP1 (0.78) | CASP1CASP7HSD17B10MAOAMAOB | |
| Hydrochloric Acid SCHEMBL23671046 | 0.82 | CASP1 (0.75) | CASP1CASP7HSD17B10MAOAMAOB | |
| SCHEMBL3204625 | 0.80 | CASP1 (0.78) | CASP1CASP7HSD17B10MAOAMAOB | |
| Hydrochloric Acid SCHEMBL5113010 | 0.78 | CASP1 (0.75) | CASP1CASP7HSD17B10MAOAMAOB | |
| SCHEMBL5543621 | 0.78 | MAOA (0.55) | MAOAMAOBCYP2A6MAPK1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118406404-A | Circuit board ink-jet printing ink stripping agent and preparation method and application thereof | 珠海市板明科技有限公司 | 2024-07-30 | — | — | CN | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-2074089-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008048991-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| US-20260022132-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | TREELINE BIOSCIENCES INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025245127-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4622716-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| WO-2025038936-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-02-20 | — | — | WO | disclosed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| CN-118406404-A | Circuit board ink-jet printing ink stripping agent and preparation method and application thereof | 珠海市板明科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024112654-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-11390733-B2 | Elastomeric formulations comprising branched EPDM polymers | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-1992016524-A1 | BENZO-FUSED LACTAMS PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0275131-B1 | HERBICIDAL OXOINDANES AND TETRAHYDRONAPHTHALENES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1992-09-23 | — | — | EP | disclosed |
| US-5095038-A | Antiinflammatory, antiallergens | ICI AMERICAS INC. (US) | 1992-03-10 | — | — | US | disclosed |
| US-5032598-A | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents | MERCK & CO., INC. (US) | 1991-07-16 | — | — | US | disclosed |
| EP-0431945-A2 | Antiarrhythmic agents | MERCK & CO. INC. (US) | 1991-06-12 | — | — | EP | disclosed |
| EP-0337765-A2 | Acylsulfonamide derivatives of alpha-carbocyclyltoluic acids used as leukotriene antagonists | ICI AMERICAS INC. (US) | 1989-10-18 | — | — | EP | disclosed |
| CN-1030575-A | Oxo-1,2-indane and tetrahydronaphthalenherbicide herbicide | SHELL INT RESEARCH (NL) | 1989-01-25 | — | — | CN | disclosed |
| EP-0275131-A1 | Herbicidal oxoindanes and tetrahydronaphthalenes | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022132-A1 | SPIROCYCLIC DIHYDROPYRANOPYRIMIDINE KRAS INHIBITORS | KRAS, NRAS, G3BP2 | CASP1 3330/4885CASP7 2499/4885HSD17B10 2796/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | CASP1 2266/4885CASP7 1485/4885HSD17B10 2152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.